<DOC>
	<DOCNO>NCT00859781</DOCNO>
	<brief_summary>The purpose study test effectiveness experimental drug , 177Lu-J591 combination ketoconazole hydrocortisone prostate cancer .</brief_summary>
	<brief_title>177Lu Radiolabeled Monoclonal Antibody HuJ591 ( 177Lu-J591 ) Ketoconazole Patients With Prostate Cancer</brief_title>
	<detailed_description>This research do standard treatment prostate cancer return ( PSA elevate ) surgery and/or radiation progress initial hormonal therapy curative . Existing treatment , ketoconazole use part study may decrease PSA temporarily , unfortunately cancer continue grow . This experimental drug design seek prostate cancer cell deliver lethal dose radiation area cancer , normal area . Some normal organ ( liver , kidney bone marrow ) receive radiation dose within acceptable limit . The experimental drug study include antibody ( abbreviate : mAb ) call `` J591 '' . It protein molecule bind specific site prostate cancer cell . A energetic radioactive ( unstable atom ) metal call 177Lutetium ( abbreviate : 177Lu ) attach J591 antibody . The fully assemble drug call `` 177Lu-J591 '' . The study assess potential energy give radioactive compound kill cancer cell . This study may also involve use 111Indium ( abbreviate 111In ) . This also energetic radioactive particle , generally give enough energy kill cancer cell , allow researcher take picture . This radioactive particle also attach J591 antibody ( call 111In-J591 ) serve placebo ( treatment active medicine ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate previously treat surgery and/or radiotherapy . Biochemical progression ( rise PSA ) medical surgical castration High risk systemic progression define : 1 . Rising PSA define either : 2 . Absolute PSA &gt; 20 ng/mL AND/OR 3 . PSA double time &lt; 8 month No evidence local recurrence distant metastases Age &gt; 18 year . Serum testosterone &lt; 50 ng/ml Patients capable fathering child must agree use effective method contraception duration trial . Subjects bisphosphonate therapy must stable dose must start therapy &gt; 4 week prior protocol therapy . Ability understand willingness sign write informed consent document . Use red blood cell platelet transfusion within 4 week treatment Use hematopoietic growth factor within 4 week treatment Prior cytotoxic chemotherapy and/or radiation therapy within 4 week treatment Prior radiation therapy encompass &gt; 25 % skeleton Prior treatment 89Strontium 153Samarium contain compound ( e.g . Metastron® , Quadramet® ) Platelet count &lt; 150,000/mm3 Absolute neutrophil count ( ANC ) &lt; 2,000/mm3 Hematocrit &lt; 30 percent Hemoglobin &lt; 10 g/dL Abnormal coagulation profile ( PT INR , PTT ) &gt; 1.3x ULN Serum creatinine &gt; 2.5 mg/dL AST ( SGOT ) &gt; 2x ULN Bilirubin ( total ) &gt; 1.5x ULN Serum calcium &gt; 11 mg/dL Active serious infection Active angina pectoris NY Heart Association Class IIIIV Karnofsky Performance Status &lt; 70 Life expectancy &lt; 12 month History deep vein thrombosis and/or pulmonary embolus within 3 month study entry Other serious illness ( e ) involve cardiac , respiratory , CNS , renal , hepatic hematological organ system might preclude completion study interfere determination causality adverse effect experience study . Prior investigational therapy ( medication device ) within 6 week treatment . Prior use ketoconazole purpose prostate cancer therapy Known history HIV . Currently active malignancy nonmelanoma skin cancer .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate</keyword>
</DOC>